GSK PLC SEC Filings

GSK plc executed purchases of its ordinary shares on 03 October 2025, acquiring 350,000 shares through BNP Paribas under its ongoing buyback programme. The disclosed per-share price range shows trades between 1,598.00p and 1,649.00p

Since 30 September 2025 the company has bought 1,252,000 ordinary shares in total. After this transaction GSK holds 248,716,844 shares in treasury and reports 4,066,691,695 ordinary shares in issue (excluding treasury shares), giving treasury shares a 6.12% share of total voting rights. Detailed execution-level prices and transaction references are provided for trades on XLON and BATE.

GSK plc disclosed a purchase of 335,000 ordinary shares on 02 October 2025 executed by BNP Paribas under its announced buyback programme. The announcement says the bought shares will be held as Treasury shares and that, since 30 September 2025, the Company has purchased a total of 902,000 ordinary shares.

Following this transaction the Company holds 248,366,844 ordinary shares in treasury and has 4,067,040,496 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,067,040,496 and the percentage of voting rights attributable to Treasury shares is 6.11%.

GSK plc reports that, acting through BNP Paribas SA, it purchased 262,000 ordinary shares of 31 3/4 pence each on 01 October 2025 as part of its existing buyback programme under the non-discretionary agreement announced on 30 September 2025. The announcement states that since 30 September 2025 the Company has purchased 567,000 ordinary shares. The purchased shares will be held as treasury shares. Following the purchase, GSK will hold 248,031,844 ordinary shares in treasury and will have 4,067,375,496 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,067,375,496, and the percentage of voting rights attributable to ordinary shares held in treasury is 6.10%. The filing includes a detailed schedule of individual trades executed on London exchanges and notes the purchase venues and aggregated trade information.

GSK plc notifies the market of its issued share capital and total voting rights. The company reported 4,315,407,340 ordinary shares of 31.25 pence each, of which 247,769,844 are held in treasury, producing a total of 4,067,637,496 voting rights. The notice states this figure may be used by shareholders as the denominator when determining whether they must notify changes in their holdings under applicable disclosure rules and provides an email contact for notifications.

GSK plc announced that, acting through BNP Paribas SA, it purchased 305,000 ordinary shares on 30 September 2025 as part of its existing buyback programme under a non-discretionary agreement with the Broker. The purchases will be held as Treasury shares. Following this transaction, GSK will hold 247,769,844 ordinary shares in treasury and have 4,067,637,496 ordinary shares in issue (excluding treasury shares), giving a total number of voting rights of 4,067,637,496. The Company confirms the percentage of voting rights attributable to treasury shares is 6.09%. The filing includes an aggregated trading-venue schedule and detailed individual transaction prices and reference numbers.

GSK plc announced the third tranche of its previously declared £2.0 billion share buyback programme: an additional tranche of up to £0.3 billion commencing 30 September 2025 and expected to complete by 19 December 2025. Purchases will be executed under a non-discretionary agreement with BNP Paribas and any Ordinary Shares bought under this tranche will be held as Treasury shares. The Programme is being implemented within GSK's existing repurchase authority of up to 413,957,879 Ordinary Shares and in accordance with applicable market regulations. No repurchases will be made in the United States or for American Depositary Receipts.

GSK has appointed Luke Miels as CEO Designate; he will assume full responsibilities and join the Board on 1 January 2026. Miels, currently Chief Commercial Officer since 2017, led global medicines and vaccines commercial activities and played a central role in building GSK's specialty medicines portfolio.

Current CEO Dame Emma Walmsley will step down from the Board on 31 December 2025 and remain employed until 30 September 2026 to support an orderly transition, with continued salary, pension, benefits and certain post-employment support. GSK states long-term sales expectations of more than £40 billion (risk-adjusted) by 2031.

Remuneration for Miels is set at a £1,375,000 starting salary, on-target bonus of 150% (max 300%), a 2026 LTI grant of 7.25x salary (envisaged to rise to 8x in 2027), pension and benefits aligned to UK workforce, and potential meaningful increases over subsequent years to reach median global BioPharma pay.

GSK plc filed a Form 6-K reporting transaction notifications. The filing lists share transactions with an ISIN GB00BN7SWP63 at a price of 3.0300 and multiple entries for ISIN US37733W2044 at a price of $40.7387. The document repeats the US ISIN and price across several lines and provides an aggregated section header, but it does not disclose volumes, the parties to the transactions, transaction types, or any explanatory context. The filing is dated September 22, 2025.

GSK plc reported share repurchases under its ongoing buyback programme. On 18 September 2025 the Company, through Merrill Lynch International, purchased 15,858 ordinary shares at prices between 1,471.00p and 1,480.00p, with an aggregated per-share reference of 1,476.54p. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 29,330,461 ordinary shares. After these transactions GSK holds 247,464,844 shares in treasury and has 4,067,938,124 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,067,938,124 and the percentage of voting rights attributable to treasury shares is stated as 6.08%.